Centella asiatica – Ayurved Healing

Mandukaparni (Centella asiatica) vs Brahmi: Resolving the Identity Confusion in Ayurveda

Dr. Meera Iyer — Thu, 20 Aug 2026 10:30:00 +0000

Mandukaparni (Centella asiatica) vs Brahmi: Resolving the Identity Confusion in Ayurveda

Few naming problems in Ayurvedic pharmacognosy are as persistent as the Brahmi–Mandukaparni confusion. In prescriptions, product labels, regional practice and household use, the word “Brahmi” may point to Bacopa monnieri, Centella asiatica, or a mixture of both. This matters because the two plants are botanically distinct, carry different pharmacognostic markers, and are used with different practical expectations in Ayurveda and in contemporary herbal practice.

The cleanest way to resolve the confusion is to keep the traditional name and the botanical name together. In current pharmacopoeial usage, Brahmi is Bacopa monnieri and Mandukaparni is Centella asiatica. Both are valuable medhya-type herbs, but they should not be treated as interchangeable without knowing exactly which plant is being used.

The Two Plants in Question

The following comparison gives the practical identification points most relevant for practitioners, students and consumers. It combines pharmacopoeial identity, plant morphology and modern marker-compound distinctions.

Feature	Brahmi: Bacopa monnieri	Mandukaparni: Centella asiatica
Pharmacopoeial identity	Brahmi whole plant is Bacopa monnieri (Linn.) Wettst.	Mandukaparni whole plant is Centella asiatica (Linn.) Urban
Modern botanical family	Plantaginaceae; older Ayurvedic pharmacopoeial listings may place it under Scrophulariaceae	Apiaceae, also called Umbelliferae
Growth habit	Small, succulent, prostrate or creeping herb of wet and damp places	Stoloniferous creeping herb, rooting at nodes
Leaf character	Simple, opposite, sessile, obovate-oblong leaves, slightly bitter in taste	Orbicular-reniform leaves with crenate margin and cordate base; the leaf form explains the “manduka-parni” name
Common marker compounds	Triterpenoid saponins, especially bacosides	Pentacyclic triterpenoids such as asiaticoside, madecassoside, asiatic acid and madecassic acid
API rasa	Madhura, tikta, kashaya	Tikta
API guna	Laghu, sara	Laghu, sara
API virya	Shita	Shita
API vipaka	Madhura	Madhura
API karma highlights	Medhya, rasayana, kapha-vatahara, ayushya, matiprada	Medhya, rasayana, deepana, kapha-pittahara
API dose	1–3 g powder	5–10 g dried drug

Where the Confusion Comes From

The confusion is not simply a modern marketing error. The Ayurvedic Pharmacopoeia of India itself shows why regional language can mislead. The Brahmi monograph for Bacopa monnieri includes vernacular names such as “Manduka Parni” in Hindi and “Mandukaparni” in Kannada, while the Mandukaparni monograph for Centella asiatica includes “Brahmi” in Hindi, Punjabi and Urdu, and “Brahmi soppu” in Kannada. In other words, the same vernacular names have crossed over between the two plants.

This is why the botanical name is not a minor technical detail. A label that says only “Brahmi” may still be ambiguous unless it states Bacopa monnieri, Centella asiatica, or both with quantities.

Classical Context

In the Rasayana chapter of the Charaka Samhita, Mandukaparni appears specifically in the medhya rasayana passage: Mandukaparni juice, Yashtimadhu powder with milk, Guduchi juice, and Shankhapushpi paste are named as rasayana preparations that support life, strength, agni, complexion, voice and medha. Brahmi also appears in Charaka in a separate rasayana context, including Aindra Rasayana. This supports the need to read the classical name in context rather than forcing every “Brahmi” and “Mandukaparni” reference into one plant.

Modern pharmacopoeial standardization resolves the practical dispensing question by assigning Brahmi to Bacopa monnieri and Mandukaparni to Centella asiatica. That is the safest convention for prescriptions, product labels, research reports and consumer guidance.

Pharmacognostic Differences

When the fresh plant is available, the difference is visible. Bacopa monnieri has small, opposite, fleshy leaves and a wetland habit. Centella asiatica has longer petioles and kidney-shaped to nearly circular leaves, arising from a creeping stoloniferous plant. Microscopic and phytochemical profiling also separates them clearly.

Identification point	Bacopa monnieri	Centella asiatica
Habit	Juicy, succulent, glabrous herb rooting at nodes	Small creeping herb with slender stem, rooting at nodes
Leaves	Simple, opposite, sessile, fleshy	Simple leaves with elongated petiole and reniform outline
Microscopy	Plenty of air cavities, matching its wet habitat	Dorsiventral leaf histology with differentiated midrib and striated cuticle
Phytochemical distinction	Alkaloids, saponins, glycosides and tannins reported in screening	Alkaloids, saponins, glycosides and tannins reported, with flavonoids also noted in comparative screening

Why the Distinction Matters Clinically

Both herbs are used in mind-and-nervous-system contexts, but the practical emphasis differs. Bacopa monnieri is the plant most often examined in standardized oral extracts for cognitive performance, attention and memory-related outcomes. Centella asiatica has a strong identity in skin, connective tissue, wound support and venous microcirculation contexts, while also being used traditionally as a medhya herb.

Practical goal	Preferred botanical identity	Why botanical identity matters
Memory, learning and attention support in adults	Bacopa monnieri	The best-known human cognitive trials used standardized Bacopa extracts, commonly over repeated daily use for weeks
Calming medhya support where sleepiness is not a concern	Bacopa monnieri, selected carefully	Bacopa is commonly described as a calming cognitive herb and may be mildly sedating in some users
Skin recovery, scars and topical wound-support formulations	Centella asiatica	Centella triterpenoids are widely associated with connective-tissue and skin-repair applications
Venous insufficiency and venous microcirculation support	Centella asiatica triterpenic fraction under professional guidance	Purified Centella triterpenic fractions have been used in clinical work on venous hypertension and chronic venous insufficiency
Classical medhya rasayana context of Mandukaparni swarasa	Centella asiatica	The pharmacopoeial Mandukaparni identity is Centella, and Charaka specifically names Mandukaparni juice in the medhya rasayana passage
Ayurvedic Brahmi formulations such as Brahmi Ghrita or Saraswatarishta	Usually Bacopa monnieri under pharmacopoeial convention	The API Brahmi monograph lists Brahmi Ghrita and Saraswatarishta among important formulations for Brahmi

Bacopa monnieri: Brahmi in Pharmacopoeial Usage

In the Ayurvedic Pharmacopoeia of India, Brahmi is defined as the dried whole plant of Bacopa monnieri. Its official Ayurvedic properties are madhura-tikta-kashaya rasa, laghu-sara guna, shita virya and madhura vipaka. The monograph lists medhya, rasayana, kaphahara, vatahara, ayushya and matiprada among its actions, and gives 1–3 g powder as the dose.

Contemporary Bacopa preparations usually specify bacoside content. Standardized extracts in adult trials commonly fall around 300–450 mg per day, while traditional crude-herb dosing is higher. Because Bacopa may cause gastrointestinal discomfort and mild sedation in some users, it is commonly taken with food and selected cautiously in people already using sedatives, anticholinergic drugs, thyroid medication or multiple prescription medicines.

Centella asiatica: Mandukaparni in Pharmacopoeial Usage

In the Ayurvedic Pharmacopoeia of India, Mandukaparni is defined as the dried whole plant of Centella asiatica. Its official Ayurvedic properties are tikta rasa, laghu-sara guna, shita virya and madhura vipaka. The API dose is 5–10 g of the dried drug.

Centella contains triterpenoid compounds such as asiaticoside, madecassoside, asiatic acid and madecassic acid. In practical use it is often associated with skin, wound, connective-tissue and venous applications, while in Ayurveda it also retains a medhya identity through Mandukaparni. It is also eaten as a food in some regions, but concentrated extracts should be treated differently from culinary use.

Safety Profiles: Key Differences

Correct identification matters because the two plants do not carry identical cautions. The following table summarizes practical safety distinctions without replacing individualized medical advice.

Safety point	Bacopa monnieri	Centella asiatica
Common adverse effects	Gastrointestinal effects such as increased stool frequency, nausea and abdominal cramps are the main practical concern	Usually mild, transient effects such as headache, dizziness, bloating, diarrhea or nausea may occur with oral extracts
Sedation	May be mildly sedating; use caution with sedatives or when alertness is required	Drowsiness can occur in some users, especially with higher oral intake
Thyroid caution	Animal data and clinical cautions suggest extra care in thyroid disease or with thyroid hormone medication	No comparable thyroid-specific caution is central to the Centella monograph, but medical review is still appropriate
Drug-interaction caution	Use caution with anticholinergic or cholinergic drugs and medicines metabolized through CYP pathways	Use caution with liver disease, sedatives and complex medication regimens
Liver caution	No common hepatotoxicity signal is central to standard Bacopa use at usual doses	Rare clinically apparent liver injury has been reported with oral Centella products; stop use and seek care if jaundice, dark urine, severe fatigue or right-upper-abdominal pain occurs
Pregnancy and breastfeeding	Avoid concentrated supplements unless prescribed by a qualified practitioner or healthcare provider	Avoid concentrated supplements unless prescribed by a qualified practitioner or healthcare provider

Dosage and Preparation: Do Not Transfer Doses Across Plants

A Bacopa dose should not be copied onto a Centella product, and a Centella triterpenic-fraction dose should not be copied onto a Bacopa product. The pharmacopoeial powder dose for Brahmi is 1–3 g, while the API dose for Mandukaparni is 5–10 g. Modern standardized extracts add another layer because the marker compounds and percentage standardizations differ.

Brahmi powder: API dose is 1–3 g of Bacopa monnieri powder.
Bacopa standardized extract: Adult trial and clinical-reference ranges commonly use 300–450 mg per day of extract standardized to bacosides or bacopa glycosides.
Mandukaparni dried drug: API dose is 5–10 g of Centella asiatica.
Centella triterpenic fraction: Venous microcirculation studies have used purified triterpenic fractions such as 60–120 mg daily under study conditions.

Traditional Formulations and Single-Herb Use

Brahmi and Mandukaparni appear in different practical formats. The API Brahmi monograph lists formulations such as Saraswatarishta, Brahmi Ghrita, Brahmi Vati, Sarasvata Churna and Smritisagara Rasa. For Mandukaparni, Charaka’s medhya rasayana passage specifically names Mandukaparni swarasa, or fresh juice, as the preparation in that context.

This distinction is useful at the prescription desk. If a clinician intends Brahmi Ghrita under the pharmacopoeial Brahmi identity, Bacopa monnieri is the expected plant. If the intended herb is Mandukaparni swarasa, the pharmacopoeial identity is Centella asiatica.

When Both Are Used Together

Some formulations and modern supplements use both Bacopa and Centella. That can be a deliberate choice, but it should be transparent. A combined product should state both botanical names and their respective quantities, rather than hiding the mixture under the single word “Brahmi.”

Using both herbs together does not remove the need for dose clarity. It increases the need for it, because each plant contributes its own constituents, actions and cautions.

Practical Recommendations for Consumers

The safest buying rule is simple: never rely on the name “Brahmi” alone. Look for the Latin botanical name, the part used, the extract ratio or standardization, the dose per serving, and quality-testing information.

For Bacopa: the label should say Bacopa monnieri and, for extracts, ideally specify bacosides or bacopa glycosides.
For Centella: the label should say Centella asiatica and, for extracts, ideally specify asiaticoside, madecassoside, total triterpenes or TTFCA-type standardization.
For fresh herbs: Bacopa has small opposite fleshy leaves and a wetland habit; Centella has kidney-shaped leaves on longer petioles and creeps by stolons.
For prescriptions: ask the practitioner whether the intended plant is Bacopa monnieri, Centella asiatica, or both.
For children, pregnancy, breastfeeding, chronic illness or prescription medicines: use only under qualified professional guidance.

The Clean Resolution

The most practical resolution is not to argue over which regional usage is “wrong,” but to standardize communication. In current pharmacopoeial usage, write and dispense Brahmi (Bacopa monnieri) when Bacopa is intended, and Mandukaparni (Centella asiatica) when Centella is intended.

Both herbs have legitimate Ayurvedic value. The problem begins only when one name is used without botanical clarity. Accurate naming protects classical integrity, clinical intent, product quality and patient safety.

Medical Disclaimer: This article is for educational purposes only and does not replace individualized advice. Consult a qualified Ayurvedic practitioner or healthcare provider before using Brahmi, Mandukaparni or any concentrated herbal supplement, especially if you are pregnant, breastfeeding, giving it to a child, taking prescription medicines, or living with thyroid, liver, neurological or cardiovascular conditions.

References

Centella Asiatica vs Bacopa: Two Brain Herbs Confused by Everyone

Dr. Meera Iyer — Fri, 06 Mar 2026 20:03:15 +0000

In Indian herbal commerce, the name Brahmi may be used for either Bacopa monnieri or Centella asiatica. The two plants are not botanically interchangeable, even though both have been associated with memory, intellect, and mental well-being. This overlap in common names can cause consumers to purchase a different plant from the one used in a clinical trial or described in a particular monograph.

Official Indian pharmacopoeial nomenclature separates them clearly. The Ayurvedic Pharmacopoeia of India identifies Brahmi as Bacopa monnieri and Mandukaparni as Centella asiatica. Product labels, therefore, should state the complete botanical name rather than relying on “Brahmi” alone.

The distinction matters because the plants belong to different botanical families, contain different characteristic compounds, and have not been investigated equally for the same clinical purposes.

The Naming Problem: One Common Name, Two Botanical Species

Bacopa monnieri and Centella asiatica have both circulated under the name Brahmi in regional practice, trade, popular literature, and supplement marketing. Reviews of their nomenclature have specifically noted that this shared name can lead to substitution or uncertainty about the botanical identity of commercial products.

In the Ayurvedic Pharmacopoeia of India, the identities are unambiguous: Brahmi is Bacopa monnieri, while Mandukaparni is Centella asiatica. These pharmacopoeial identities provide a practical standard for manufacturing, prescribing, purchasing, and discussing the two herbs.

The frequently cited Medhya Rasayana passage in the Charaka Samhita should also be described accurately. In Chikitsa Sthana 1.3.30–31, the four intellect-supporting preparations are Mandukaparni juice, Yashtimadhu powder taken with milk, Guduchi juice, and Shankhapushpi paste. The passage names Mandukaparni, not a four-herb group containing both Brahmi and Mandukaparni.

This does not make the two plants interchangeable. A classical therapeutic category such as Medhya can include more than one substance, while each substance retains its own botanical identity, preparation, dose, and clinical context.

How to Tell the Plants Apart

The plants are readily distinguishable when their leaves and growth habits are examined. Botanical identification is more dependable than a vernacular name printed on a packet or repeated by a retailer.

Centella asiatica (Mandukaparni) is a creeping herb with rounded, kidney-shaped, or broadly fan-shaped leaves borne on conspicuous petioles. The margins are usually crenate or scalloped. Its small flowers occur in compact umbels close to the nodes. It commonly grows in moist ground, marshy places, and other wet habitats.

Bacopa monnieri (Brahmi) is also a low, creeping herb, but its leaves are small, opposite, thick, succulent, and nearly sessile. They are generally oblong, obovate, or spatulate rather than rounded and fan-shaped. The flowers are solitary and typically white to pale blue or violet.

A useful field distinction is therefore straightforward: a rounded leaf on a long stalk suggests Centella, while a small, fleshy, nearly stalkless leaf arranged opposite another leaf suggests Bacopa.

Neither plant is confined to a single part of India. Bacopa monnieri occurs widely in tropical and subtropical wet habitats, while Centella asiatica has an extensive Old World distribution extending from parts of Africa and Asia to Australia and the western Pacific. Commercial origin alone cannot establish identity.

Different Chemistry and Different Extracts

The characteristic phytochemical profiles of the two plants are distinct. This is one reason that milligram amounts cannot be compared directly and one species should not be substituted for the other in a formula or clinical protocol.

Centella Triterpenes

The best-known constituents of Centella asiatica include the pentacyclic triterpenes asiaticoside, madecassoside, asiatic acid, and madecassic acid. The proportions vary with the plant material, geographical source, processing method, and type of extract.

Centella preparations used in experiments and clinical studies have included whole-herb products, hydroalcoholic extracts, and defined triterpenic fractions. These preparations are not automatically equivalent. A product standardized to total triterpenes may differ substantially from one standardized to a particular percentage of asiaticoside or madecassoside.

Laboratory investigations have examined effects involving extracellular-matrix formation, inflammatory signalling, oxidative stress, vascular function, and nervous-system pathways. Such mechanistic findings help explain why Centella has been studied in skin, wound, and venous conditions, but they do not establish that every oral or topical Centella product will produce the same clinical result.

Bacopa Saponins

Bacopa monnieri contains a complex group of dammarane-type triterpenoid saponins commonly described as bacosides and bacopasides. “Bacoside A” is not one isolated molecule; it is a mixture that includes bacoside A3, bacopaside II, bacopasaponin C, and a jujubogenin-related saponin.

The historical term “bacoside B” has not always been used consistently, so a label stating only “bacosides” does not fully describe an extract. Analytical results can also differ according to whether ultraviolet spectrophotometry, high-performance liquid chromatography, or another method was used. Percentages obtained by different assays should not be treated as directly interchangeable.

Preclinical work has examined Bacopa in relation to cholinergic and monoaminergic signalling, antioxidant defence, synaptic activity, and memory-related brain processes. Human conclusions, however, should be based on controlled clinical outcomes rather than extrapolated from cellular or animal mechanisms alone.

What the Human Cognitive Trials Indicate

The human cognitive literature is more substantial for Bacopa monnieri than for Centella asiatica, although the magnitude and consistency of Bacopa’s effects vary by study, extract, population, outcome measure, and duration.

A 2014 meta-analysis identified nine randomized, placebo-controlled Bacopa trials involving 518 participants. Data suitable for quantitative analysis represented 437 participants. The pooled findings favoured Bacopa for certain measures of attention-related processing speed, including choice reaction time and Trail Making Test Part B, but the authors also called for larger, well-designed comparative trials.

One frequently cited randomized trial enrolled 46 healthy adults and compared 300 mg daily of a standardized Bacopa monnieri extract with placebo. Assessments were conducted at baseline, five weeks, and twelve weeks. At twelve weeks, the Bacopa group had improvements in several measures, including visual information processing, learning rate, memory consolidation, and state anxiety. The delayed pattern is consistent with Bacopa being investigated as a regularly administered herb rather than an immediate stimulant.

A separate systematic review of randomized trials found the most consistent signal in memory free-recall tasks. Results for many other cognitive domains were absent, inconsistent, or measured too differently for a broad conclusion. It is therefore more accurate to describe Bacopa as having promising evidence for selected memory and attention outcomes than as a universally proven cognitive enhancer.

Many adult trials have used approximately 300 mg per day of a standardized extract for about twelve weeks, but that number is not a universal Ayurvedic or pharmacological dose. Extract concentration, plant part, analytical method, formulation, health status, and concomitant medicines all affect whether two products are comparable.

Centella and Cognitive Outcomes

Human cognitive studies of Centella asiatica are fewer and generally smaller. A study involving 28 healthy older adults evaluated daily doses of 250, 500, or 750 mg for two months. Some measures of working memory and mood changed during the study, particularly at the higher dose, but the small sample and multiple dose groups limit the certainty and generalizability of the result.

A later systematic review and meta-analysis did not provide strong support for broad cognitive improvement with Centella. The available trials differed in participants, preparations, doses, treatment periods, and cognitive tests. Some findings relating to alertness or mood were of interest, but Centella cannot be considered clinically equivalent to Bacopa on the basis of the current cognitive literature.

Mandukaparni nevertheless has an authentic place in Ayurveda as one of the substances used in the Medhya Rasayana context. That classical use should be presented on its own terms rather than supported with exaggerated or substituted modern trial claims.

Centella in Wound and Venous Research

Centella asiatica and its triterpenic preparations have also been investigated for wound healing, scar-related applications, and chronic venous insufficiency. This area of study is more characteristic of Centella than of Bacopa, but the findings still require careful interpretation.

A systematic review of Centella in wound healing concluded that it might assist aspects of healing, including angiogenesis, but the included studies used varied preparations, models, wound types, and outcome measures. This heterogeneity prevents all Centella creams, extracts, and triterpene fractions from being treated as equivalent.

A systematic review of oral Centella preparations for chronic venous insufficiency found possible improvements in certain symptoms and physiological measurements. The authors advised caution because of limitations in study quality and reporting. Centella products should not replace wound assessment, infection treatment, compression therapy, vascular evaluation, or other indicated medical care.

Head-to-Head Comparison

The following comparison separates verified botanical identity from areas that remain dependent on the particular preparation and quality of the clinical evidence.

Parameter	Centella asiatica	Bacopa monnieri
Ayurvedic Pharmacopoeia name	Mandukaparni	Brahmi
Botanical family	Apiaceae	Plantaginaceae
Growth form	Creeping herb with rounded leaves on distinct petioles	Creeping succulent herb with small, opposite, nearly sessile leaves
Characteristic constituents	Asiaticoside, madecassoside, asiatic acid, and madecassic acid	Bacosides, bacopasides, and related dammarane-type saponins
Classical point	Mandukaparni is included in Charaka’s four Medhya Rasayana preparations	Recognized as Brahmi in the Ayurvedic Pharmacopoeia of India
Human cognitive literature	Limited, small, and methodologically varied	Multiple randomized trials and systematic reviews, with the clearest findings in selected memory and attention measures
Other studied areas	Wound healing, scar-related preparations, and chronic venous insufficiency	Memory performance, attention-related processing, and learning measures
Common preparation problem	Total-triterpene and single-marker extracts may differ	“Bacoside” percentages may differ according to extract and assay method
Common adverse effects	Topical irritation or allergy; mild digestive or other nonspecific effects may occur	Nausea, abdominal cramping, and increased stool frequency are among the more commonly reported effects
Important caution	Rare cases of clinically apparent liver injury have been reported	Possible cholinergic, thyroid-related, and drug-metabolism interactions require clinical consideration

Matching the Plant to the Intended Use

For a person comparing products with published human memory trials, Bacopa monnieri is the more directly studied species. This does not guarantee benefit, and it does not mean that every Bacopa powder or capsule matches the extracts used in the trials. The botanical name, extract specification, dose, and treatment duration must all be considered.

For a person considering a Centella preparation for a scar, wound, swelling, or venous symptoms, the exact formulation and clinical diagnosis are important. An oral extract used in a venous-insufficiency trial is not equivalent to a cosmetic cream, and neither should be used to self-manage an infected wound, a non-healing ulcer, sudden leg swelling, or suspected vascular disease.

Ayurvedic prescribing also involves more than matching one herb to one symptom. A qualified practitioner considers the verified drug identity, formulation, processing, route of administration, digestive tolerance, accompanying substances, individual constitution, disease stage, and other treatments already being used.

What to Check on the Label

A trustworthy label should allow the purchaser and practitioner to determine exactly which plant and preparation are present. A common name without botanical details is inadequate for comparing the product with either pharmacopoeial standards or clinical trials.

Complete Latin name: The label should state either Bacopa monnieri or Centella asiatica. “Brahmi” alone does not establish the species.
Plant part: Look for a declaration of the whole plant, aerial parts, leaves, or other material actually used.
Preparation type: Distinguish whole-herb powder from an extract. For an extract, check the extraction ratio, solvent where disclosed, and quantity equivalent to the starting herb.
Marker compounds and assay method: A bacoside or triterpene percentage is more useful when the analytical method is also identified. Percentages generated by different methods may not be comparable.
Batch and manufacturer details: Check the batch number, expiry date, storage instructions, manufacturer, and applicable regulatory information.
Independent quality verification: Certifications such as USP Verified or appropriate NSF certification can provide information about identity, declared ingredients, contaminants, and manufacturing quality. They do not prove that a supplement will be effective for a particular condition.

In the United States, dietary supplements are not approved by the Food and Drug Administration for safety and effectiveness before they are marketed in the same manner as medicines. This makes accurate identity, responsible manufacturing, transparent testing, and professional guidance especially important.

Safety and Interactions

Bacopa monnieri commonly causes gastrointestinal effects such as nausea, abdominal cramping, or increased stool frequency in some users. Because Bacopa may have cholinergic activity and may affect thyroid-related or drug-metabolizing pathways, people using prescription medicines should obtain professional advice before taking a concentrated extract.

Centella asiatica can cause topical irritation or allergic contact reactions. Oral use has generally been associated with mild and nonspecific adverse effects, but rare cases of clinically apparent liver injury have been reported. A person who develops jaundice, dark urine, marked itching, persistent nausea, or unusual fatigue after starting an herbal product should stop it and seek medical assessment.

Pregnancy, breastfeeding, childhood, liver disease, thyroid disorders, cardiovascular conditions, planned surgery, and concurrent medication use require individualized guidance. The safety of a culinary or traditional preparation should not automatically be applied to a concentrated standardized extract.

The Practical Conclusion

Brahmi and Mandukaparni should not be presented as two names for one botanical drug. Under the Ayurvedic Pharmacopoeia of India, Brahmi is Bacopa monnieri and Mandukaparni is Centella asiatica. Both have associations with intellect-supporting use, but Charaka’s specific four-item Medhya Rasayana passage names Mandukaparni together with Yashtimadhu, Guduchi, and Shankhapushpi.

For modern product selection, the Latin binomial is the starting point. The plant part, extract type, marker compounds, analytical method, dose, and duration determine whether a supplement resembles the preparation described in a pharmacopoeia or clinical trial. Reading “Brahmi” on the front of a bottle is not enough.

This article is for educational purposes and does not constitute medical advice. Consult a qualified Ayurvedic practitioner or healthcare provider before using either herb, particularly during pregnancy or breastfeeding, for a child, alongside prescription medicines, or when managing a diagnosed health condition.